Evaluation of Immunogenicity and Safety of VARIVAX ™ Passage Extension 34 (PE34) Process in Children (V210-A03)

Condition:   Varicella Interventions:   Biological: VARIVAX™ PE34 Process;   Biological: VARIVAX™ 2016 Commercial Process;   Biological: M-M-R II™ Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials